facebook
twitter
youtube
linkedin

Home - Resources - Consensus statement of the VASCERN HTAD Working Group (January 23, 2019)
March 20 2023

Consensus statement of the VASCERN HTAD Working Group (January 23, 2019)

In patients with HTAD, Fluoroquinolones should be used with caution because of a possible risk for exacerbation of aortic disease.  The use of alternatives is preferred while awaiting further evidence.

Skip to content